Division of Hematology, Mayo Clinic, Rochester, MN.
J Clin Oncol. 2022 Aug 10;40(23):2600-2608. doi: 10.1200/JCO.22.00495. Epub 2022 Jun 14.
With the introduction of multiple new effective therapeutic options for the treatment of macroglobulinemia, a structured approach to management of this rare lymphoma is currently needed. A review of phase II and III treatment trials over the past 20 years was performed, and high-quality trials are summarized in this manuscript. Because of the lack of large prospective trials comparing different classes of therapy, a uniform recommendation applicable to all patients cannot be made, and the approach must be individualized incorporating patient preferences, comorbidities, and the range of therapeutic toxicities. Therapeutic options for patients with newly diagnosed and previously treated macroglobulinemia are presented on the basis of the best available evidence in the literature.
随着治疗巨球蛋白血症的多种新的有效治疗选择的引入，目前需要对这种罕见淋巴瘤的治疗进行结构化处理。对过去 20 年的 II 期和 III 期治疗试验进行了回顾，并在本文中总结了高质量的试验。由于缺乏比较不同治疗类别的大型前瞻性试验，因此无法针对所有患者做出统一的推荐，必须根据患者的偏好、合并症和治疗毒性范围进行个体化处理。根据文献中最佳可用证据，为新诊断和既往治疗的巨球蛋白血症患者提供了治疗选择。
